Research Desk Line-up: Alcobra Post Earnings Coverage
LONDON, UK / ACCESSWIRE / June 26, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Gilead Sciences, Inc. (NASDAQ: GILD), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=GILD. The Company announced on June 23, 2017, that the Committee for Medicinal Products for Human Use (CHMP), and the scientific committee of the European Medicines Agency (EMA) have adopted a positive opinion on the Company's Marketing Authorization Application (MAA). Gilead filed the application for Vosevi, an investigational, once-daily, single tablet regimen of sofosbuvir 400 mg, velpatasvir 100 mg, and voxilaprevir 100 mg, which was intended for the treatment of chronic hepatitis C virus (HCV)-infected patients. For immediate access to our complimentary reports, including today's coverage, register for free now at:
Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Alcobra Ltd (NASDAQ: ADHD) for due-diligence and potential coverage as the Company announced its financial results for Q1 2017 which ended on March 31, 2017, and also provided a corporate update. Tune in to our site to register for a free membership, and be among the early birds that get our report on Alcobra when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on GILD; also brushing on ADHD. Go directly to your stock of interest and access today's free coverage at:
This update comes at the heels of the announcement made on January 20, 2017, under which the Company announced that the MAA for the single tablet regimen of sofosbuvir 400 mg, velpatasvir 100 mg, and voxilaprevir 100 mg (SOF/VEL/VOX) for the treatment of chronic hepatitis C virus (HCV)-infected patients, was fully validated by the EMA and was under further assessment.
The MAA for SOF/VEL/VOX is supported by data from four Phase-3 studies, which included two studies, namely POLARIS-1 and POLARIS-4, evaluated under 12 weeks of the single tablet regimen in patients with genotypes of 1-6 HCV infection previously treated unsuccessfully with DAA-containing regimens, including NS5A inhibitors. Under these two tests, 97% of the treated patients achieved the primary efficacy endpoint of SVR12.
The other two tests, namely POLARIS-2 and POLARIS-3, evaluated 8 weeks of SOF/VEL/VOX in DAA-naive patients with genotypes 1-6 HCV infection. In POLARIS-2 test, 95% of the patients treated with SOF/VEL/VOX achieved the primary efficacy endpoint of SVR-12. The final test, i.e., POLARIS-3, reported 93% of the patients with genotype-3 infection and cirrhosis treated with SOF/VEL/VOX, achieved the primary efficacy endpoint of SVR12.
Sofosbuvir was granted marketing authorization, as a single agent, in the European Union on January 16, 2014, under the trade name Sovaldi, for use in combination with other agents. Also, the single tablet regimen of sofosbuvir and ledipasvir received marketing authorization in the European Union, under the trade name Harvoni, on November 18, 2014. The single tablet version of sofosbuvir and velpatasvir received marketing authorization in the EU on July 08, 2016, under the trade name Epclusa.
Gilead HCV Treatment Portfolio
According to the Company, the direct-acting antiviral treatment has transformed the ability to treat hepatitis C. However, some patients were unable to be cured with these regimens, effective and well-tolerated therapies are still necessary for them. The Company viewed the submission of this application as a step to deliver enhanced treatment options for the life-threatening disease to the maximum possible patients in Europe and around the world.
Gilead Sciences, Inc. announced on January 12, 2017, a $22 million fund for the HIV cure grants program, which will support 12 new HIV cure research projects. These tests focus on three key segments, namely, translational research, efficacy studies in animal models, and community perspectives of HIV cure.
The SOF/VEL/VOX for the treatment of HCV was initially reviewed by the EMA under the centralized licensing procedure for all 28 member states of the European Union, Norway, and Iceland. The review followed an accelerated procedure reserved for medicinal products expected to be of major public health interest. The Company also submitted a New Drug Application to the FDA for SOF/VEL/VOX on December 08, 2016.
Last Close Stock Review
On Friday, June 23, 2017, the stock closed the trading session at $70.52, marginally rising 0.06% from its previous closing price of $70.48. A total volume of 22.90 million shares have exchanged hands, which was higher than the 3-month average volume of 8.08 million shares. Gilead Sciences' stock price advanced 9.66% in the last one month and 4.46% in the past three months. The stock is trading at a PE ratio of 7.45 and has a dividend yield of 2.95%. The stock currently has a market cap of $92.24 billion.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily